Plan to attend the next From Concept to Commercialization in-person seminar featuring Dan Liebler with “Protypia: A Late-Career Biotech Game That Paid Off” on Wednesday, October 18 , 2023 at 4pm in 202 Light Hall. With over 30 years of experience at the interface of analytical technology, chemical biology and disease research, Dr. Liebler is an internationally-recognized research leader in the fields of proteomics, cancer proteogenomics, chemical biology and toxicology. This will not be recorded.
About the speaker:
Daniel Liebler, Ph.D. is an internationally-recognized research leader in the fields of proteomics, cancer proteogenomics, chemical biology and toxicology. With over 30 years of experience at the interface of analytical technology, chemical biology and disease research, Dr. Liebler led multidisciplinary programs at the University of Arizona and Vanderbilt University School of Medicine funded by the National Institutes of Health, industry and private philanthropy. At Vanderbilt, Dr. Liebler's team laid the groundwork for the integration of proteomic technologies into cancer therapeutics and diagnostics. Dr. Liebler left Vanderbilt in 2016 to launch Protypia, which provides drug target and system analysis to leading pharmaceutical and biotechnology companies. Protypia was acquired by Inotiv in July 2022 and Dr. Liebler serves as Vice President, Proteomic Technology.